Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Purpose Galunisertib, a TGF-β inhibitor, has demonstrated antitumor effects in preclinical and radiographic responses in some patients with malignant glioma. This Phase 1b/2a trial investigated the clinical benefit of combining galunisertib with temozolomide-based radiochemotherapy (TMZ/RTX) in pati...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Invest New Drugs
Main Authors: Wick, Antje, Desjardins, Annick, Suarez, Cristina, Forsyth, Peter, Gueorguieva, Ivelina, Burkholder, Tiana, Cleverly, Ann Louise, Estrem, Shawn T., Wang, Shuaicheng, Lahn, Michael M., Guba, Susan C., Capper, David, Rodon, Jordi
Format: Artigo
Sprog:Inglês
Udgivet: Springer US 2020
Fag:
Phase II Studies
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497674/
https://ncbi.nlm.nih.gov/pubmed/32140889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00910-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker